Natixis Protalix Bio Therapeutics, Inc. Transaction History
Natixis
- $17.6 Billion
- Q3 2024
Shares
3 transactions
Others Institutions Holding PLX
# of Institutions
50Shares Held
3.58MCall Options Held
61.1KPut Options Held
36.2K-
Jim Simons Renaissance Technologies LLC | New York, Ny956KShares$1.67 Million0.0% of portfolio
-
Gsa Capital Partners LLP London, X0435KShares$761,6220.03% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny374KShares$654,0740.0% of portfolio
-
Black Rock Inc. New York, NY333KShares$583,0490.0% of portfolio
-
Stratos Wealth Partners, Ltd.270KShares$472,5000.0% of portfolio
About Protalix BioTherapeutics, Inc.
- Ticker PLX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,753,400
- Market Cap $87.1M
- Description
- Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...